• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

立体定向放疗增加肿瘤微环境中的功能性抑制性调节 T 细胞。

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.

机构信息

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

出版信息

Cancer Immunol Res. 2017 Nov;5(11):992-1004. doi: 10.1158/2326-6066.CIR-17-0040. Epub 2017 Oct 2.

DOI:10.1158/2326-6066.CIR-17-0040
PMID:28970196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5793220/
Abstract

Radiotherapy (RT) enhances innate and adaptive antitumor immunity; however, the effects of radiation on suppressive immune cells, such as regulatory T cells (Treg), in the tumor microenvironment (TME) are not fully elucidated. Although previous reports suggest an increased Treg infiltration after radiation, whether these Tregs are functionally suppressive remains undetermined. To test the hypothesis that RT enhances the suppressive function of Treg in the TME, we selectively irradiated implanted tumors using the small animal radiation research platform (SARRP), which models stereotactic radiotherapy in human patients. We then analyzed tumor-infiltrating lymphocytes (TIL) with flow-cytometry and functional assays. Our data showed that RT significantly increased tumor-infiltrating Tregs (TIL-Treg), which had higher expression of CTLA-4, 4-1BB, and Helios compared with Tregs in nonirradiated tumors. This observation held true across several tumor models (B16/F10, RENCA, and MC38). We found that TIL-Tregs from irradiated tumors had equal or improved suppressive capacity compared with nonirradiated tumors. Our data also indicated that after RT, Tregs proliferated more robustly than other T-cell subsets in the TME. In addition, after RT, expansion of Tregs occurred when T-cell migration was inhibited using Fingolimod, suggesting that the increased Treg frequency was likely due to preferential proliferation of intratumoral Treg after radiation. Our data also suggested that Treg expansion after irradiation was independent of TGFβ and IL33 signaling. These data demonstrate that RT increased phenotypically and functionally suppressive Tregs in the TME. Our results suggest that RT might be combined effectively with Treg-targeting agents to maximize antitumor efficacy. .

摘要

放疗(RT)增强了固有和适应性抗肿瘤免疫;然而,辐射对肿瘤微环境(TME)中抑制性免疫细胞(如调节性 T 细胞[Treg])的影响尚未完全阐明。尽管先前的报告表明辐射后 Treg 浸润增加,但这些 Tregs 是否具有功能抑制性仍未确定。为了验证 RT 增强 TME 中 Treg 抑制功能的假设,我们使用小动物放射研究平台(SARRP)选择性地对植入的肿瘤进行放射,该平台模拟了人类患者的立体定向放射治疗。然后,我们使用流式细胞术和功能测定分析了肿瘤浸润淋巴细胞(TIL)。我们的数据表明,RT 显著增加了肿瘤浸润的 Treg(TIL-Treg),与未照射肿瘤中的 Treg 相比,TIL-Treg 表达更高的 CTLA-4、4-1BB 和 Helios。这一观察结果在几种肿瘤模型(B16/F10、RENCA 和 MC38)中均成立。我们发现,来自照射肿瘤的 TIL-Treg 具有与未照射肿瘤相当或改善的抑制能力。我们的数据还表明,在 RT 后,Treg 在 TME 中的增殖比其他 T 细胞亚群更旺盛。此外,在用 Fingolimod 抑制 T 细胞迁移后,RT 后 Treg 发生扩增,这表明 Treg 频率的增加可能是由于辐射后肿瘤内 Treg 的优先增殖。我们的数据还表明,照射后 Treg 的扩增与 TGFβ 和 IL33 信号无关。这些数据表明,RT 增加了 TME 中表型和功能抑制性 Treg。我们的研究结果表明,RT 可能与 Treg 靶向药物联合使用,以最大限度地提高抗肿瘤疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/6aebe2034252/nihms936118f6a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/9d27d8476c1a/nihms936118f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/8e2179e86430/nihms936118f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/3e40d0963146/nihms936118f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/34ac50e7fa09/nihms936118f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/c633ad0de813/nihms936118f5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/6aebe2034252/nihms936118f6a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/9d27d8476c1a/nihms936118f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/8e2179e86430/nihms936118f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/3e40d0963146/nihms936118f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/34ac50e7fa09/nihms936118f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/c633ad0de813/nihms936118f5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8a9/5793220/6aebe2034252/nihms936118f6a.jpg

相似文献

1
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.立体定向放疗增加肿瘤微环境中的功能性抑制性调节 T 细胞。
Cancer Immunol Res. 2017 Nov;5(11):992-1004. doi: 10.1158/2326-6066.CIR-17-0040. Epub 2017 Oct 2.
2
Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.热量限制会损害辐射后肿瘤微环境中的调节性 T 细胞,并激活效应 T 细胞。
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1341-1349. doi: 10.1016/j.ijrobp.2021.02.029. Epub 2021 Feb 26.
3
Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.新型 Tim-3 调节性 T 细胞效应表型导致头颈部癌症患者的抑制功能增强。
Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. Epub 2018 Apr 30.
4
High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.高剂量分割放疗在前列腺肿瘤中既能诱导抗肿瘤免疫又能诱导免疫抑制反应。
Clin Cancer Res. 2021 Mar 1;27(5):1505-1515. doi: 10.1158/1078-0432.CCR-20-2293. Epub 2020 Nov 20.
5
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.抗 CTLA-4 激活肿瘤内 NK 细胞,并与 IL15/IL15Rα 复合物结合增强肿瘤控制。
Cancer Immunol Res. 2019 Aug;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. Epub 2019 Jun 25.
6
Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.肿瘤微环境决定调节性 T 细胞表型:上调的免疫检查点增强抑制功能。
J Immunother Cancer. 2019 Dec 4;7(1):339. doi: 10.1186/s40425-019-0785-8.
7
MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment.MondoA-硫氧还蛋白相互作用蛋白轴在结直肠癌微环境中维持调节性 T 细胞的特性和功能。
Gastroenterology. 2021 Aug;161(2):575-591.e16. doi: 10.1053/j.gastro.2021.04.041. Epub 2021 Apr 24.
8
Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.具有高度免疫抑制特性的调节性T细胞在乳腺肿瘤微环境中的优先积累。
Oncotarget. 2017 May 16;8(20):33159-33171. doi: 10.18632/oncotarget.16565.
9
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.索拉非尼缓解肿瘤微环境中效应 T 细胞的细胞内和细胞外抑制作用,增强抗肿瘤免疫。
Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.
10
Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.抗 PD-1 检查点治疗可促进调节性 T 细胞的功能和存活。
J Immunol. 2021 Nov 15;207(10):2598-2607. doi: 10.4049/jimmunol.2001334. Epub 2021 Oct 4.

引用本文的文献

1
Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy.癌症免疫疗法与放疗和/或化疗联合应用:作用机制与临床治疗
MedComm (2020). 2025 Aug 31;6(9):e70346. doi: 10.1002/mco2.70346. eCollection 2025 Sep.
2
CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer.细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂与放疗协同作用,可重塑肿瘤微环境,并增强抗程序性死亡受体配体1(PD-L1)免疫疗法在三阴性乳腺癌中的抗肿瘤效果。
J Biomed Sci. 2025 Aug 20;32(1):79. doi: 10.1186/s12929-025-01173-3.
3

本文引用的文献

1
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation.现代放射治疗概念及辐射对免疫激活的影响
Front Oncol. 2016 Jun 20;6:141. doi: 10.3389/fonc.2016.00141. eCollection 2016.
2
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.异基因造血细胞移植(alloHCT)围手术期给予白细胞介素-33(IL-33)可使受体调节性T细胞扩增,从而保护小鼠免受急性移植物抗宿主病(GVHD)的影响。
Blood. 2016 Jul 21;128(3):427-39. doi: 10.1182/blood-2015-12-684142. Epub 2016 May 24.
3
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model.
Roles of the phagocytosis checkpoint in radiotherapy.
吞噬作用检查点在放射治疗中的作用。
Cell Death Dis. 2025 Aug 20;16(1):630. doi: 10.1038/s41419-025-07921-5.
4
The Role of Predictive Biomarkers in Modern Prostate Cancer Radiotherapy: A Literature Review on Personalised Treatment Strategies and the Prediction of Adverse Effects.预测性生物标志物在现代前列腺癌放疗中的作用:关于个性化治疗策略及不良反应预测的文献综述
Life (Basel). 2025 Jul 2;15(7):1062. doi: 10.3390/life15071062.
5
YTHDFs as radiotherapy checkpoints in tumor immunity.YTHDFs作为肿瘤免疫中的放射治疗检查点。
J Exp Med. 2025 Aug 4;222(8). doi: 10.1084/jem.20250272. Epub 2025 Jun 5.
6
Radiation-Induced Lymphopenia Prognosis and Risk Factors in Postmastectomy Radiotherapy Patients.乳房切除术后放疗患者放射性淋巴细胞减少症的预后及危险因素
Cancer Manag Res. 2025 May 28;17:1047-1058. doi: 10.2147/CMAR.S522807. eCollection 2025.
7
Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment.在癌症治疗中具有多种作用机制的免疫调节纳米平台。
Nanomedicine (Lond). 2025 Jun;20(11):1321-1338. doi: 10.1080/17435889.2025.2500906. Epub 2025 May 7.
8
Immune Modulation Through Stereotactic Radiotherapy: The Role of TBX21, GATA-3, FoxP3, and RORɣt.立体定向放射治疗的免疫调节作用:TBX21、GATA-3、FoxP3和RORɣt的作用
Medicina (Kaunas). 2025 Apr 13;61(4):717. doi: 10.3390/medicina61040717.
9
Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities.利用放射疗法改善免疫治疗效果:原理、进展与研究重点
Clin Transl Immunology. 2025 Apr 8;14(4):e70030. doi: 10.1002/cti2.70030. eCollection 2025.
10
Advances in nanoparticle-based radiotherapy for cancer treatment.基于纳米粒子的癌症放射治疗进展。
iScience. 2024 Dec 14;28(1):111602. doi: 10.1016/j.isci.2024.111602. eCollection 2025 Jan 17.
在卵巢癌异种移植人源化小鼠模型中,抗CCR4单克隆抗体通过调节肿瘤浸润性调节性T细胞增强抗肿瘤免疫力。
Oncoimmunology. 2015 Dec 10;5(3):e1090075. doi: 10.1080/2162402X.2015.1090075. eCollection 2016 Mar.
4
Vaccines for established cancer: overcoming the challenges posed by immune evasion.已确立的癌症疫苗:克服免疫逃避带来的挑战。
Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11.
5
Interleukin-35 Limits Anti-Tumor Immunity.白细胞介素-35限制抗肿瘤免疫。
Immunity. 2016 Feb 16;44(2):316-29. doi: 10.1016/j.immuni.2016.01.013. Epub 2016 Feb 9.
6
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.放疗与免疫检查点抑制剂治疗:增敏作用及协同作用的潜在机制。
Lancet Oncol. 2015 Oct;16(13):e498-509. doi: 10.1016/S1470-2045(15)00007-8.
7
CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation.细胞周期蛋白依赖性激酶抑制剂1A(CDKN1A)在暴露于电离辐射后调节朗格汉斯细胞的存活并促进调节性T细胞的生成。
Nat Immunol. 2015 Oct;16(10):1060-8. doi: 10.1038/ni.3270. Epub 2015 Sep 7.
8
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.转化生长因子-β信号通路小分子抑制剂加鲁尼西替(LY2157299一水合物)的临床开发
Drug Des Devel Ther. 2015 Aug 10;9:4479-99. doi: 10.2147/DDDT.S86621. eCollection 2015.
9
Role of Local Radiation Therapy in Cancer Immunotherapy.局部放疗在癌症免疫治疗中的作用。
JAMA Oncol. 2015 Dec;1(9):1325-32. doi: 10.1001/jamaoncol.2015.2756.
10
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.在肝癌模型以及来自患者的离体全肿瘤组织样本中,用加鲁尼塞替(LY2157299)抑制转化生长因子-β信号传导的作用。
Oncotarget. 2015 Aug 28;6(25):21614-27. doi: 10.18632/oncotarget.4308.